Concurrent chemotherapy using taxane plus cisplatin <i>versus</i> cisplatin alone in high-risk nasopharyngeal carcinoma patients with suboptimal response to induction chemotherapy.

Zhang, Ya-Ni; Chen, Yu-Pei; Li, Ji-Bin; Lu, Tai-Xiang; Han, Fei; Chen, Chun-Yan

Concurrent chemotherapy using taxane plus cisplatin versus cisplatin alone in high-risk nasopharyngeal carcinoma patients with suboptimal response to induction chemotherapy.

Zhang, Ya-Ni; Chen, Yu-Pei; Li, Ji-Bin; Lu, Tai-Xiang; Han, Fei; Chen, Chun-Yan.

Afiliação

Zhang YN; Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
Chen YP; State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, China.
Li JB; United Laboratory of Frontier Radiotherapy Technology of Sun Yat-sen University & Chinese Academy of Sciences Ion Medical Technology Co., Ltd.
Lu TX; Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
Han F; State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, China.
Chen CY; United Laboratory of Frontier Radiotherapy Technology of Sun Yat-sen University & Chinese Academy of Sciences Ion Medical Technology Co., Ltd.

Ther Adv Med Oncol ; 15: 17588359231177016, 2023.

Article em En | MEDLINE | ID: mdl-37323188

Palavras-chave

concurrent chemotherapy; induction chemotherapy; nasopharyngeal carcinoma; prognosis; taxane; tumor response

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google